How metformin affects various malignancies by means of microRNAs: a brief review

Metformin known as the first-line orally prescribed drug for lowering blood glucose in type II diabetes (T2DM) has recently found various therapeutic applications including in cancer. Metformin has been studied for its influences in prevention and treatment of cancer through multiple mechanisms such...

Descripción completa

Detalles Bibliográficos
Autores principales: Alimoradi, Nahid, Firouzabadi, Negar, Fatehi, Reihaneh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8045276/
https://www.ncbi.nlm.nih.gov/pubmed/33849540
http://dx.doi.org/10.1186/s12935-021-01921-z
_version_ 1783678651080900608
author Alimoradi, Nahid
Firouzabadi, Negar
Fatehi, Reihaneh
author_facet Alimoradi, Nahid
Firouzabadi, Negar
Fatehi, Reihaneh
author_sort Alimoradi, Nahid
collection PubMed
description Metformin known as the first-line orally prescribed drug for lowering blood glucose in type II diabetes (T2DM) has recently found various therapeutic applications including in cancer. Metformin has been studied for its influences in prevention and treatment of cancer through multiple mechanisms such as microRNA (miR) regulation. Alteration in the expression of miRs by metformin may play an important role in the treatment of various cancers. MiRs are single-stranded RNAs that are involved in gene regulation. By binding to the 3′UTR of target mRNAs, miRs influence protein levels. Irregularities in the expression of miRs that control the expression of oncogenes and tumor suppressor genes are associated with the onset and progression of cancer. Metformin may possess an effect on tumor prevention and progression by modifying miR expression and downstream pathways. Here, we summarize the effect of metformin on different types of cancer by regulating the expression of various miRs and the associated downstream molecules.
format Online
Article
Text
id pubmed-8045276
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-80452762021-04-14 How metformin affects various malignancies by means of microRNAs: a brief review Alimoradi, Nahid Firouzabadi, Negar Fatehi, Reihaneh Cancer Cell Int Review Metformin known as the first-line orally prescribed drug for lowering blood glucose in type II diabetes (T2DM) has recently found various therapeutic applications including in cancer. Metformin has been studied for its influences in prevention and treatment of cancer through multiple mechanisms such as microRNA (miR) regulation. Alteration in the expression of miRs by metformin may play an important role in the treatment of various cancers. MiRs are single-stranded RNAs that are involved in gene regulation. By binding to the 3′UTR of target mRNAs, miRs influence protein levels. Irregularities in the expression of miRs that control the expression of oncogenes and tumor suppressor genes are associated with the onset and progression of cancer. Metformin may possess an effect on tumor prevention and progression by modifying miR expression and downstream pathways. Here, we summarize the effect of metformin on different types of cancer by regulating the expression of various miRs and the associated downstream molecules. BioMed Central 2021-04-13 /pmc/articles/PMC8045276/ /pubmed/33849540 http://dx.doi.org/10.1186/s12935-021-01921-z Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Alimoradi, Nahid
Firouzabadi, Negar
Fatehi, Reihaneh
How metformin affects various malignancies by means of microRNAs: a brief review
title How metformin affects various malignancies by means of microRNAs: a brief review
title_full How metformin affects various malignancies by means of microRNAs: a brief review
title_fullStr How metformin affects various malignancies by means of microRNAs: a brief review
title_full_unstemmed How metformin affects various malignancies by means of microRNAs: a brief review
title_short How metformin affects various malignancies by means of microRNAs: a brief review
title_sort how metformin affects various malignancies by means of micrornas: a brief review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8045276/
https://www.ncbi.nlm.nih.gov/pubmed/33849540
http://dx.doi.org/10.1186/s12935-021-01921-z
work_keys_str_mv AT alimoradinahid howmetforminaffectsvariousmalignanciesbymeansofmicrornasabriefreview
AT firouzabadinegar howmetforminaffectsvariousmalignanciesbymeansofmicrornasabriefreview
AT fatehireihaneh howmetforminaffectsvariousmalignanciesbymeansofmicrornasabriefreview

Ejemplares similares